{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:39:27Z","timestamp":1769524767268,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Trillium Therapeutics"},{"DOI":"10.13039\/100018844","name":"Drs. Martin and Dorothy Spatz Charitable Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018844","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00262-021-03051-x","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:02:37Z","timestamp":1631617357000},"page":"919-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides"],"prefix":"10.1007","volume":"71","author":[{"given":"Oleg","family":"Kruglov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa D. S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Minic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Uger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"3051_CR1","first-page":"857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857\u2013866","journal-title":"Arch Dermatol"},{"key":"3051_CR2","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P et al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol 34:2698\u20132704. https:\/\/doi.org\/10.1200\/JCO.2015.65.9789","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3051_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","volume":"38","author":"MS Khodadoust","year":"2020","unstructured":"Khodadoust MS, Rook AH, Porcu P et al (2020) Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome: a multicenter phase II study. J Clin Oncol 38:20\u201328. https:\/\/doi.org\/10.1200\/JCO.19.01056","journal-title":"J Clin Oncol"},{"key":"3051_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00277-018-3406-6","volume":"98","author":"K Ono","year":"2019","unstructured":"Ono K, Onishi Y, Kobayashi M et al (2019) gammadelta T cell clonal proliferation early after PD-1 blockade. Ann Hematol 98:219\u2013220. https:\/\/doi.org\/10.1007\/s00277-018-3406-6","journal-title":"Ann Hematol"},{"key":"3051_CR5","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","volume":"378","author":"L Ratner","year":"2018","unstructured":"Ratner L, Waldmann TA, Janakiram M, Brammer JE (2018) Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med 378:1947\u20131948. https:\/\/doi.org\/10.1056\/NEJMc1803181","journal-title":"N Engl J Med"},{"key":"3051_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S et al (2017) PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552:121\u2013125. https:\/\/doi.org\/10.1038\/nature24649","journal-title":"Nature"},{"key":"3051_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","volume":"148","author":"F Cetinozman","year":"2012","unstructured":"Cetinozman F, Jansen PM, Vermeer MH, Willemze R (2012) Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides. Arch Dermatol 148:1379\u20131385. https:\/\/doi.org\/10.1001\/archdermatol.2012.2089","journal-title":"Arch Dermatol"},{"key":"3051_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ajh.21960","volume":"86","author":"DA Wada","year":"2011","unstructured":"Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI (2011) Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sezary syndrome. Am J Hematol 86:325\u2013327. https:\/\/doi.org\/10.1002\/ajh.21960","journal-title":"Am J Hematol"},{"key":"3051_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","volume":"34","author":"K Kantekure","year":"2012","unstructured":"Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, Odum N, Wasik M (2012) Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am J Dermatopathol 34:126\u2013128. https:\/\/doi.org\/10.1097\/DAD.0b013e31821c35cb","journal-title":"Am J Dermatopathol"},{"key":"3051_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/614619","volume":"2013","author":"PA Oldenborg","year":"2013","unstructured":"Oldenborg PA (2013) CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol 2013:614619. https:\/\/doi.org\/10.1155\/2013\/614619","journal-title":"ISRN Hematol"},{"key":"3051_CR11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP (2000) Role of CD47 as a marker of self on red blood cells. Science 288:2051\u20132054","journal-title":"Science"},{"key":"3051_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1517\/14728222.2013.733699","volume":"17","author":"DR Soto-Pantoja","year":"2013","unstructured":"Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD (2013) Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets 17:89\u2013103. https:\/\/doi.org\/10.1517\/14728222.2013.733699","journal-title":"Expert Opin Ther Targets"},{"key":"3051_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K (2017) Cancer immunotherapy targeting the CD47\/SIRPalpha axis. Eur J Cancer 76:100\u2013109. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.013","journal-title":"Eur J Cancer"},{"key":"3051_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jaad.2016.03.011","volume":"75","author":"R Akel","year":"2016","unstructured":"Akel R, Kurban M, Abbas O (2016) CD47 expression for in situ and invasive cutaneous epithelial lesions. J Am Acad Dermatol 75:434\u2013436. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.011","journal-title":"J Am Acad Dermatol"},{"key":"3051_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M, Chen H, Odunsi K (2016) The CD47 \u201cdon\u2019t eat me signal\u201d is highly expressed in human ovarian cancer. Gynecol Oncol 143:393\u2013397. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.325","journal-title":"Gynecol Oncol"},{"key":"3051_CR16","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","volume":"118","author":"MP Chao","year":"2011","unstructured":"Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL (2011) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118:4890\u20134901. https:\/\/doi.org\/10.1182\/blood-2011-02-338020","journal-title":"Blood"},{"key":"3051_CR17","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26:2538\u20132545. https:\/\/doi.org\/10.1038\/leu.2012.141","journal-title":"Leukemia"},{"key":"3051_CR18","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1073\/pnas.1600007113","volume":"113","author":"GW Krampitz","year":"2016","unstructured":"Krampitz GW, George BM, Willingham SB et al (2016) Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 113:4464\u20134469. https:\/\/doi.org\/10.1073\/pnas.1600007113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286\u2013299. https:\/\/doi.org\/10.1016\/j.cell.2009.05.045","journal-title":"Cell"},{"key":"3051_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","volume":"138","author":"JM RendtlewDanielsen","year":"2007","unstructured":"RendtlewDanielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T (2007) Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 138:756\u2013760. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06729.x","journal-title":"Br J Haematol"},{"key":"3051_CR21","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer JP, Gentles AJ et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109:6662\u20136667. https:\/\/doi.org\/10.1073\/pnas.1121623109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000452530","volume":"40","author":"C Yang","year":"2016","unstructured":"Yang C, Gao S, Zhang H, Xu L, Liu J, Wang M, Zhang S (2016) CD47 is a potential target for the treatment of laryngeal squamous cell carcinoma. Cell Physiol Biochem 40:126\u2013136. https:\/\/doi.org\/10.1159\/000452530","journal-title":"Cell Physiol Biochem"},{"key":"3051_CR23","doi-asserted-by":"publisher","first-page":"E6215","DOI":"10.1073\/pnas.1520032112","volume":"112","author":"H Zhang","year":"2015","unstructured":"Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, Gilkes DM, He J, Semenza GL (2015) HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A 112:E6215\u2013E6223. https:\/\/doi.org\/10.1073\/pnas.1520032112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hep.27070","volume":"60","author":"TK Lee","year":"2014","unstructured":"Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, Ng IO (2014) Blockade of CD47-mediated cathepsin S\/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60:179\u2013191. https:\/\/doi.org\/10.1002\/hep.27070","journal-title":"Hepatology"},{"key":"3051_CR25","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms16023391","volume":"16","author":"H Wang","year":"2015","unstructured":"Wang H, Tan M, Zhang S et al (2015) Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci 16:3391\u20133404. https:\/\/doi.org\/10.3390\/ijms16023391","journal-title":"Int J Mol Sci"},{"key":"3051_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271\u2013285. https:\/\/doi.org\/10.1016\/j.cell.2009.05.046","journal-title":"Cell"},{"key":"3051_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","volume":"23","author":"PS Petrova","year":"2017","unstructured":"Petrova PS, Viller NN, Wong M et al (2017) TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res 23:1068\u20131079. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1700","journal-title":"Clin Cancer Res"},{"key":"3051_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","volume":"3","author":"LDS Johnson","year":"2019","unstructured":"Johnson LDS, Banerjee S, Kruglov O et al (2019) Targeting CD47 in Sezary syndrome with SIRPalphaFc. Blood Adv 3:1145\u20131153. https:\/\/doi.org\/10.1182\/bloodadvances.2018030577","journal-title":"Blood Adv"},{"key":"3051_CR29","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29:2598\u20132607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630","journal-title":"J Clin Oncol"},{"key":"3051_CR30","first-page":"181","volume":"128","author":"LJ Picker","year":"1987","unstructured":"Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA (1987) Immunophenotypic criteria for the diagnosis of non-Hodgkin\u2019s lymphoma. Am J Pathol 128:181\u2013201","journal-title":"Am J Pathol"},{"key":"3051_CR31","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 11: 155\u201368."},{"key":"3051_CR32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.micinf.2003.07.005","volume":"5","author":"S Flamant","year":"2003","unstructured":"Flamant S, Lebastard M, Pescher P, Besmond C, Milon G, Marchal G (2003) Enhanced cloning efficiency of mouse bone marrow macrophage progenitors correlates with increased content of CSF-1 receptor of their progeny at low oxygen tension. Microbes Infect 5:1064\u20131069","journal-title":"Microbes Infect"},{"key":"3051_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1126\/science.8456300","volume":"259","author":"DK Dalton","year":"1993","unstructured":"Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739\u20131742","journal-title":"Science"},{"key":"3051_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.206","author":"X Wu","year":"2014","unstructured":"Wu X, Schulte BC, Zhou YW, Haribhai D, Mackinnon AC, Plaza JA, Williams CB, Hwang ST (2014) Depletion of M2-like tumor-associated macrophages delays cutaneous T cell lymphoma development in vivo. J Invest Dermatol. https:\/\/doi.org\/10.1038\/jid.2014.206","journal-title":"J Invest Dermatol"},{"key":"3051_CR35","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/jid.2011.89","volume":"131","author":"X Wu","year":"2011","unstructured":"Wu X, Sells RE, Hwang ST (2011) Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin. J Invest Dermatol 131:1727\u20131734. https:\/\/doi.org\/10.1038\/jid.2011.89","journal-title":"J Invest Dermatol"},{"key":"3051_CR36","doi-asserted-by":"publisher","first-page":"279ra39","DOI":"10.1126\/scitranslmed.3010302","volume":"7","author":"R Watanabe","year":"2015","unstructured":"Watanabe R, Gehad A, Yang C et al (2015) Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 7:279ra39. https:\/\/doi.org\/10.1126\/scitranslmed.3010302","journal-title":"Sci Transl Med."},{"key":"3051_CR37","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.18632\/oncotarget.2031","volume":"5","author":"Y Huang","year":"2014","unstructured":"Huang Y, Litvinov IV, Wang Y et al (2014) Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. Oncotarget 5:4418","journal-title":"Oncotarget"},{"key":"3051_CR38","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/jid.2012.13","volume":"132","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang Y, Yu R et al (2012) Molecular markers of early-stage mycosis fungoides. J Investig Dermatol 132:1698\u20131706","journal-title":"J Investig Dermatol"},{"key":"3051_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00403-014-1501-7","volume":"306","author":"S Morimura","year":"2014","unstructured":"Morimura S, Sugaya M, Suga H et al (2014) TOX expression in different subtypes of cutaneous lymphoma. Arch Dermatol Res 306:843\u2013849","journal-title":"Arch Dermatol Res"},{"key":"3051_CR40","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.18632\/oncotarget.5742","volume":"10","author":"BO Dulmage","year":"2019","unstructured":"Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ (2019) Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget 10:3104","journal-title":"Oncotarget"},{"key":"3051_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153550","volume":"11","author":"M Zhang","year":"2016","unstructured":"Zhang M, Hutter G, Kahn SA et al (2016) Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE 11:e0153550. https:\/\/doi.org\/10.1371\/journal.pone.0153550","journal-title":"PLoS ONE"},{"key":"3051_CR42","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3389\/fimmu.2018.02985","volume":"9","author":"PR Nath","year":"2018","unstructured":"Nath PR, Gangaplara A, Pal-Nath D, Mandal A, Maric D, Sipes JM, Cam M, Shevach EM, Roberts DD (2018) CD47 expression in natural killer cells regulates homeostasis and modulates immune response to lymphocytic choriomeningitis virus. Front Immunol 9:2985. https:\/\/doi.org\/10.3389\/fimmu.2018.02985","journal-title":"Front Immunol"},{"key":"3051_CR43","doi-asserted-by":"publisher","first-page":"38778","DOI":"10.1038\/srep38778","volume":"6","author":"X Shen","year":"2016","unstructured":"Shen X, Fu B, Liu Y, Guo C, Ye Y, Sun R, Li J, Tian Z, Wei H (2016) NKp30(+) NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep 6:38778. https:\/\/doi.org\/10.1038\/srep38778","journal-title":"Sci Rep"},{"key":"3051_CR44","first-page":"33","volume":"21","author":"M Duvic","year":"2007","unstructured":"Duvic M (2007) Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park) 21:33\u201340","journal-title":"Oncology (Williston Park)"},{"key":"3051_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","volume":"2015","author":"M Duvic","year":"2015","unstructured":"Duvic M (2015) Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sezary syndrome. Hematology Am Soc Hematol Educ Program 2015:529\u2013544. https:\/\/doi.org\/10.1182\/asheducation-2015.1.529","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3051_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2326-6066.CIR-16-0382","volume":"5","author":"E Aydin","year":"2017","unstructured":"Aydin E, Johansson J, Nazir FH, Hellstrand K, Martner A (2017) Role of NOX2-derived reactive oxygen species in NK cell-mediated control of murine melanoma metastasis. Cancer Immunol Res 5:804\u2013811. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0382","journal-title":"Cancer Immunol Res"},{"key":"3051_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1189\/jlb.0411208","volume":"90","author":"K Takeda","year":"2011","unstructured":"Takeda K, Nakayama M, Sakaki M, Hayakawa Y, Imawari M, Ogasawara K, Okumura K, Smyth MJ (2011) IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukoc Biol 90:777\u2013785. https:\/\/doi.org\/10.1189\/jlb.0411208","journal-title":"J Leukoc Biol"},{"key":"3051_CR48","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nm.3965","volume":"21","author":"RH Vonderheide","year":"2015","unstructured":"Vonderheide RH (2015) CD47 blockade as another immune checkpoint therapy for cancer. Nat Med 21:1122\u20131123. https:\/\/doi.org\/10.1038\/nm.3965","journal-title":"Nat Med"},{"key":"3051_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1397248","volume":"7","author":"L Wu","year":"2018","unstructured":"Wu L, Yu GT, Deng WW et al (2018) Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma. Oncoimmunology 7:e1397248. https:\/\/doi.org\/10.1080\/2162402X.2017.1397248","journal-title":"Oncoimmunology"},{"key":"3051_CR50","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms16023391","volume":"16","author":"H Wang","year":"2015","unstructured":"Wang H, Tan M, Zhang S et al (2015) Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci 16:3391\u20133404. https:\/\/doi.org\/10.3390\/ijms16023391","journal-title":"Int J Mol Sci"},{"key":"3051_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (2017) The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev 276:145\u2013164. https:\/\/doi.org\/10.1111\/imr.12527","journal-title":"Immunol Rev"},{"key":"3051_CR52","doi-asserted-by":"publisher","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","volume":"114","author":"NG Ring","year":"2017","unstructured":"Ring NG, Herndler-Brandstetter D, Weiskopf K et al (2017) Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A 114:E10578\u2013E10585. https:\/\/doi.org\/10.1073\/pnas.1710877114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR53","doi-asserted-by":"publisher","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","volume":"113","author":"JT Sockolosky","year":"2016","unstructured":"Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC (2016) Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A 113:E2646\u2013E2654. https:\/\/doi.org\/10.1073\/pnas.1604268113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3051_CR54","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/0008-5472.CAN-14-0037-T","volume":"74","author":"DR Soto-Pantoja","year":"2014","unstructured":"Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA, Roberts DD (2014) CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74:6771\u20136783. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0037-T","journal-title":"Cancer Res"},{"key":"3051_CR55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41467-019-14102-4","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang M, Wang X, Liu W, Wang H, Yang YG (2020) Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. Nat Commun 11:581. https:\/\/doi.org\/10.1038\/s41467-019-14102-4","journal-title":"Nat Commun"},{"key":"3051_CR56","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/2326-6066.CIR-18-0367","volume":"7","author":"PR Nath","year":"2019","unstructured":"Nath PR, Pal-Nath D, Mandal A, Cam MC, Schwartz AL, Roberts DD (2019) Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunol Res 7:1547\u20131561. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0367","journal-title":"Cancer Immunol Res"},{"key":"3051_CR57","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood.2019001744","volume":"134","author":"S Jain","year":"2019","unstructured":"Jain S, Van Scoyk A, Morgan EA et al (2019) Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas. Blood 134:1430\u20131440. https:\/\/doi.org\/10.1182\/blood.2019001744","journal-title":"Blood"},{"key":"3051_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89140","volume":"2","author":"T Yanagita","year":"2017","unstructured":"Yanagita T, Murata Y, Tanaka D et al (2017) Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight 2:e89140. https:\/\/doi.org\/10.1172\/jci.insight.89140","journal-title":"JCI Insight"},{"key":"3051_CR59","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3109\/10428194.2014.963078","volume":"56","author":"R Briski","year":"2015","unstructured":"Briski R, Feldman AL, Bailey NG et al (2015) Survival in patients with limited-stage peripheral T-cell lymphomas. Leuk Lymphoma 56:1665\u20131670. https:\/\/doi.org\/10.3109\/10428194.2014.963078","journal-title":"Leuk Lymphoma"},{"key":"3051_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 125:71\u201381. https:\/\/doi.org\/10.1182\/blood-2014-07-588236","journal-title":"Blood"},{"key":"3051_CR61","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970\u20131976. https:\/\/doi.org\/10.1200\/JCO.2012.44.7524","journal-title":"J Clin Oncol"},{"key":"3051_CR62","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ajh.22139","volume":"86","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA (2011) Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:928\u2013948. https:\/\/doi.org\/10.1002\/ajh.22139","journal-title":"Am J Hematol"},{"key":"3051_CR63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","volume":"101","author":"PA Bunn Jr","year":"1984","unstructured":"Bunn PA Jr, Foon KA, Ihde DC et al (1984) Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484\u2013487","journal-title":"Ann Intern Med"},{"key":"3051_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158297","volume":"11","author":"J Bruder Costa","year":"2016","unstructured":"Bruder Costa J, Dufeu-Duchesne T, Leroy V et al (2016) Pegylated interferon alpha-2a triggers NK-cell functionality and specific T-Cell responses in patients with chronic HBV infection without HBsAg seroconversion. PLoS ONE 11:e0158297. https:\/\/doi.org\/10.1371\/journal.pone.0158297","journal-title":"PLoS ONE"},{"key":"3051_CR65","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00262-019-02397-7","volume":"68","author":"AL Schwartz","year":"2019","unstructured":"Schwartz AL, Nath PR, Allgauer M et al (2019) Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunol Immunother 68:1805\u20131817. https:\/\/doi.org\/10.1007\/s00262-019-02397-7","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03051-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03051-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03051-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T17:24:03Z","timestamp":1647278643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03051-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3051"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03051-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OEA is a clinical investigator for Trillium Therapeutics and a recipient of a research grant from Trillium Therapeutics. No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}